Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).

Motixafortide (BKT140) displays selective toxicity toward AmL and MM cells. Motixafortide (BKT140) specifically triggers CXCR4-dependent cell death in leukemia and MM cells and it stimulates apoptotic cell death in leukemia and MM cells[2]. Treatment with Motixafortide (BKT140) can overcome IL-6 dependent proliferation and survival of ARH77 MM cells.

Tumors from animals treated with Motixafortide (BKT140) are smaller in size and weights, had larger necrotic areas and high apoptotic scores[2]. Subcutaneous injections of Motixafortide (BKT140) significantly reduces, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts.

664334-36-5

C97H144FN33O19S2

2159.52

TF14016;BL-8040;BKT140 (4-fluorobenzoyl)

DMSO:36 mg/mL (16.67 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years